Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authori

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo

The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offe

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) wit

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these s

Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral t

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that

Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the

By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy a

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and

Leerink Partners analyst Faisal Khurshid maintains Protagonist Therapeutics (NASDAQ:PTGX) with a

Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and r

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competiti

Goldman Sachs analyst Richard Law maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Neutra

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Pat

Under the terms of its January 2024 worldwide license and collaboration agreement with Takeda, the s

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Contro

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its im

Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announ

  On Tuesday, 951 companies hit new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

  On Wednesday, 216 stocks hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.